MDMA
3,4-methylenedioxy-N-methylamphetamine
Viewing r1 — Apr 20, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
MDMA (3,4-methylenedioxy-N-methylamphetamine) — ecstasy, molly — is a synthetic empathogen of the substituted amphetamine class. It is the prototypical entactogen — distinct from classical stimulants and psychedelics. It floods the brain with serotonin, norepinephrine, and dopamine, producing emotional warmth rather than stimulant energy.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
MDA, MDEA, 5-APB +4 moreMDA, MDEA, 5-APB, 6-APB, methylone, mephedrone, amphetamine show less
MDMA was first synthesized at Merck in 1912 and rediscovered by Alexander Shulgin in 1976, who introduced it to a network of therapists.[3][4] Recreational spread as "Ecstasy" led to DEA emergency scheduling in 1985. Australia permitted medical prescribing in 2023; the FDA declined approval in 2024, and MDMA remains Schedule I in the United States.[5][6]
Subjective effects include euphoria, intense warmth toward others, sociability enhancement and trust, and mild brightening of perception.[7] The experience is defined by its entactogenic quality — profound emotional openness and closeness to others unlike either stimulant energy or psychedelic expansion. Jaw clenching, elevated heart rate, and a low-mood comedown from serotonin depletion are characteristic unwanted effects.
MDMA produces no physical dependence, though moderate psychological dependence is documented;[8] no human lethal dose has been established. The main dangers — overheating, dangerous sodium imbalance, and serotonin syndrome — multiply sharply in hot environments and when combined with serotonin-active drugs.[2] MDMA is among the most studied psychoactive substances, though how much it damages serotonin-producing nerve cells in humans remains genuinely contested.[9]
History[edit]
Discovery
MDMA was first synthesized on 24 December 1912 by Anton Köllisch at Merck — not as a drug but as a chemical intermediate in a patent dispute over a blood-clotting agent.[3][10] In 1976, Alexander Shulgin developed a new synthesis and introduced MDMA to a network of therapists, who found it produced emotional openness and strengthened the therapeutic relationship.[4]
Clinical and cultural significance
By the early 1980s, hundreds of therapists were using MDMA under the name "Adam." Recreational spread as "Ecstasy" triggered DEA emergency scheduling in 1985. Two Phase 3 clinical trials later demonstrated significant PTSD symptom reduction with large effect sizes, reigniting clinical interest.[11][12]
Prohibition and modern status
MDMA was placed permanently in Schedule I in March 1986.[13] Australia became the first country to authorize medical prescribing in July 2023;[5] the US FDA declined approval in August 2024, citing concerns about study design and safety data.[6]
The name "Ecstasy" was coined as MDMA moved from therapy rooms into nightlife. Therapists had called it "Adam" — evoking a state of primal innocence. "Molly" emerged in the 2000s to suggest pure crystalline MDMA distinct from pressed tablets, though testing shows both vary widely in purity. Animal research published in 1988 finding selective damage to serotonin nerve terminals[14] set the terms of scientific and public debate for nearly four decades.
Chemistry[edit]
Structural class
MDMA belongs to the substituted methylenedioxyphenethylamine family — a group of phenethylamines sharing a 3,4-methylenedioxy ring. The molecular formula is C₁₁H₁₅NO₂ (free base).
Its closest active structural analog is MDA; MDMA's additional N-methyl group makes it more serotonin-selective, producing a more emotionally focused and less perceptually psychedelic experience.
Pharmacology[edit]
Mechanism of action
MDMA enters serotonin, norepinephrine, and dopamine transporters and reverses their function, flooding the synapse with all three neurotransmitters.[2] Unlike cocaine — which blocks reuptake without triggering release — MDMA drives active release.[2] Serotonin is released preferentially over dopamine,[1] producing MDMA's emotional warmth rather than the reward-focused drive of dopamine-preferring stimulants.[2][15]
Oxytocin release
MDMA triggers a large surge of oxytocin — a hormone linked to social bonding — peaking around 90–120 minutes after dosing.[16] Oxytocin alone cannot reproduce the full empathogenic experience,[17] indicating it is one part of a broader mechanism.
Pharmacokinetics
MDMA reaches peak blood levels about 1.5–2 hours after oral ingestion,[15] with a half-life of roughly 7–8 hours.[15][7] Critically, MDMA permanently disables the liver enzyme responsible for breaking it down after just two doses,[18][19] so blood levels rise disproportionately with repeated dosing — greatly increasing overdose risk from redosing.
Neuroscience[edit]
Where it acts
MDMA quiets the amygdala — the brain region that registers threat — reducing recognition of fearful faces[17] and increasing trust and cooperative behavior.[20] Simultaneously, it triggers a large oxytocin surge.[16] The combination of reduced threat sensitivity and heightened social bonding chemistry is thought to explain MDMA's window of therapeutic effectiveness.
Why it matters
The leading explanation for MDMA-assisted therapy centers on memory reconsolidation: traumatic memories are reactivated in a state of reduced fear, then re-stored with an updated emotional tone. MDMA specifically dampens fearful emotional memory while leaving neutral memory intact,[21] providing a biological basis for this process.
Whether MDMA produces lasting changes to brain structure and connectivity — as classical psychedelics may — or simply creates a temporary state that enables therapeutic learning, remains unresolved. Heavy users show reduced SERT availability on brain imaging[22] and small but measurable impairments in memory and cognitive flexibility,[23] though whether these represent permanent damage or reversible adaptation is debated.[9]
Subjective Effects[edit]
MDMA's subjective character is defined by its entactogenic quality — a state of intense emotional openness, warmth toward others, and interpersonal trust that feels pharmacologically distinct from any other drug category. Social settings amplify emotional closeness; stimulating environments bring the drug's energetic side to the foreground.[7]
Compared to amphetamine, MDMA produces comparable physical stimulation but with a marked emotional softening absent from dopamine-preferring stimulants.[24] Compared to MDA, the experience is less perceptually psychedelic and more emotionally focused, with a shorter duration.[2]
Effect Grid
At common doses (80–120 mg oral), the full MDMA experience manifests. Pronounced euphoria and emotional warmth dominate — a powerful sense of closeness to others, increased empathy, enhanced trust, and desire for physical and verbal intimacy. Music sounds deeply pleasurable. Emotional barriers feel temporarily dissolved, and difficult topics become approachable.
Physically, stimulation is moderate to strong: jaw clenching (trismus), teeth grinding (bruxism), pupil dilation, increased heart rate and blood pressure, mild nausea on come-up, and temperature dysregulation become common. Sweating increases. Appetite is strongly suppressed.
The core experience lasts 3–5 hours. Sleep is typically impossible for 4–6 hours after effects resolve. A period of low mood, fatigue, and reduced motivation ("comedown") commonly follows over 1–2 days.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sound sensitivity · Color enhancement · Taste enhancement · Visual haze / noise · Tracers · Auditory distortion · Brightness alteration · Color alteration · Light sensitivity · Sleep-transition hallucinations · Visual acuity enhancement · Auditory misinterpretation · Depth perception distortion · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Spatial disorientation · Synesthesia · Tinnitus · Vestibular distortion · Olfactory enhancement · Peripheral misidentification · Symmetrical texture repetition · After-images · Flashbacks · External hallucinations · Internal hallucinations · Auditory hallucinations
Tracers · Auditory distortion · Brightness alteration · Color alteration · Light sensitivity · Sleep-transition hallucinations · Visual acuity enhancement · Auditory misinterpretation · Depth perception distortion · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Spatial disorientation · Synesthesia · Tinnitus · Vestibular distortion · Olfactory enhancement · Peripheral misidentification · Symmetrical texture repetition · After-images · Flashbacks · External hallucinations · Internal hallucinations · Auditory hallucinations
Spontaneous body sensations · Stimulation · Body high · Physical fatigue · Tactile euphoria · Dry mouth · Excessive sweating · Pupil dilation · Bruxism · Muscle tension · Insomnia · Tingling / electric sensations · Dehydration sensation · Abnormal heartbeat · Bodily lightness · Heart rate perception changes · Laughter fits · Nystagmus (eye wobbles) · Restlessness · Headache · Pain suppression · Sedation · Sexual arousal enhancement · Respiratory stimulation · Nausea · Sexual arousal suppression · Breathing alteration · Vibrations / buzzing · Motor control enhancement · Brain zaps · Bodily pressures · Dizziness · Motor control impairment · Muscle relaxation · Trembling · Watery eyes · Seizure threshold reduction · Salivation · Body schema distortion · Constipation · Involuntary body movements · Nasal congestion · Yawning · Increased urination · Diarrhea · Vomiting
Physical fatigue · Tactile euphoria · Dry mouth · Excessive sweating · Pupil dilation · Bruxism · Muscle tension · Insomnia · Tingling / electric sensations · Dehydration sensation · Bodily lightness · Heart rate perception changes · Laughter fits · Nystagmus (eye wobbles) · Restlessness · Headache · Pain suppression · Sedation · Sexual arousal enhancement · Respiratory stimulation · Nausea · Sexual arousal suppression · Breathing alteration · Vibrations / buzzing · Motor control enhancement · Brain zaps · Bodily pressures · Dizziness · Motor control impairment · Muscle relaxation · Trembling · Watery eyes · Seizure threshold reduction · Salivation · Body schema distortion · Constipation · Involuntary body movements · Nasal congestion · Yawning · Increased urination · Diarrhea · Vomiting
Immersion enhancement · Aesthetic enhancement · Introspection enhancement · Thought acceleration · Cognitive impairment · Motivation suppression · Cognitive flexibility · Suggestibility enhancement · Humor enhancement · Cognitive dysphoria · Novelty enhancement · Thought connectivity · Motivation enhancement · Language enhancement · Pattern recognition enhancement · Creativity enhancement · Analysis enhancement · Conceptual thinking · Focus suppression · Memory suppression · Focus enhancement · Information processing enhancement · Thought disorganization · Confusion · Increased nature relatedness · Information processing suppression · Memory fragmentation · Memory replays · Thought loops · Thought organization · Thought deceleration · Synchronicity · Amnesia · Delirium
Thought acceleration · Cognitive impairment · Motivation suppression · Cognitive flexibility · Humor enhancement · Cognitive dysphoria · Novelty enhancement · Thought connectivity · Motivation enhancement · Language enhancement · Pattern recognition enhancement · Creativity enhancement · Analysis enhancement · Conceptual thinking · Focus suppression · Memory suppression · Focus enhancement · Information processing enhancement · Thought disorganization · Confusion · Increased nature relatedness · Information processing suppression · Memory fragmentation · Memory replays · Thought loops · Thought organization · Thought deceleration · Synchronicity · Amnesia · Delirium
Euphoria · Irritability · Catharsis · Emotional lability · Simultaneous emotions · Anhedonia · Dysphoria · Anxiety · Mania · Suicidal ideation
Emotional lability · Simultaneous emotions · Anhedonia · Dysphoria · Anxiety · Suicidal ideation
Emotional susceptibility · Communication enhancement · Sociability enhancement · Craving · Flow state · Social disconnection · Derealization · Ego inflation · Compulsive behavior reduction · Depersonalization · Boundary dissolution · Telepathic feelings · Ego dissolution
Flow state · Social disconnection · Derealization · Ego inflation · Compulsive behavior reduction · Depersonalization · Boundary dissolution · Telepathic feelings · Ego dissolution
Timeline
First alerts appear 30–45 minutes after ingestion: a subtle shift in mood, mild physical warmth, and faint butterflies in the stomach. Effects are easily missed if distracted.
Effects build rapidly over 15–30 minutes. Mood elevation accelerates, jaw tension begins, pupil dilation becomes noticeable, and a rush of warmth and sociability emerges. Brief nausea or anxiety is common during this phase.
Maximum intensity is sustained for 1. 5–2. 5 hours.
Effects gradually diminish over 1–1. 5 hours. Emotional warmth persists but stimulation fades.
The comedown unfolds over 1–1. 5 hours. Residual stimulation gives way to fatigue.
Aftereffects persist 12–48 hours. The first 24 hours often bring fatigue, low mood, reduced appetite, and difficulty concentrating — commonly called the "comedown" or "suicide Tuesday" among weekly users. Some individuals report a paradoxical afterglow of emotional openness and reflectiveness.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- rapid
- Tolerance reset
- 75 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- MDA · MDEA · 5-APB
Toxicity
Acute toxicity
No human lethal dose has been established. MDMA has been given to more than 1,100 people in clinical trials at doses up to 180 mg without drug-related serious adverse events.[25]
Hyperthermia
Overheating is the primary cause of severe MDMA toxicity. MDMA disrupts temperature regulation through multiple pathways, and hot environments, physical exertion, and crowded spaces dramatically worsen this effect.[2][26] Sustained dancing in hot venues is the most common setting for fatal overheating.
Hyponatremia
MDMA causes the body to retain water by triggering abnormal hormone release. Combined with excessive water drinking, this dilutes blood sodium to dangerous levels and can cause the brain to swell.[27][28]
Suspected water intoxication — confusion or altered consciousness after MDMA use — requires urgent medical attention. Treatment involves controlled saline and fluid restriction.[28]
Liver toxicity
MDMA can cause liver damage appearing days to weeks after use, sometimes independent of dose. Cases of acute liver failure requiring transplantation have been reported in young users.[29]
Heart and circulation
MDMA raises blood pressure and heart rate and constricts blood vessels, including coronary arteries. These effects worsen substantially with overheating. Phase 3 clinical trials found no dangerous heart rhythm changes.[11]
Serotonin syndrome
High doses or combinations with serotonin-active drugs can trigger a dangerous overload: extremely high body temperature, muscle rigidity, and cardiovascular instability that can be fatal.[15][30]
Muscle breakdown
Severe overheating from MDMA can destroy muscle tissue and trigger dangerous blood clotting disorders.[30]
Psychological risks
Acute effects can include anxiety, paranoia, and depersonalization. No psychotic episodes have been reported at therapeutic doses in controlled studies.[7] MDMA was associated with elevated substance use disorder reports in pharmacovigilance data.[8]
Long-term heavy use is linked to small but measurable deficits in cognitive flexibility, working memory, and long-term memory recall.[23] Reduced brain volume in memory regions has been correlated with recent use intensity.[31] Whether these reflect permanent damage or reversible adaptation remains debated.[9][32]
Tolerance & dependence
Tolerance builds within a single session — supplemental doses produce weaker effects than the initial dose.[33] Serotonin stores deplete rapidly, and full recovery is estimated at several weeks to months.[22]
Physical withdrawal produces no classical symptoms on stopping.[34] Clinical trial participants showed no abuse liability at therapeutic doses,[11] though recreational use patterns show moderate dependence potential.[8]
Drug interactions
MDMA's interaction risk comes from three mechanisms: serotonin flooding, cardiovascular strain, and enzyme inhibition.
The most dangerous combinations involve drugs that also raise serotonin. MAO inhibitors (phenelzine, tranylcypromine, moclobemide) block serotonin breakdown while MDMA simultaneously floods the synapse — the combination can produce fatal overheating, muscle breakdown, and organ failure.[35] Tramadol and high-dose dextromethorphan carry similar risk.[35]
SSRIs and SNRIs block MDMA's primary mechanism, substantially reducing its effects.[36] Stimulants — amphetamines, cocaine, methylphenidate — add to cardiovascular strain.[33] Other entactogens (MDA, 6-APB, mephedrone) compound serotonergic toxicity.
MDMA permanently disables the liver enzyme CYP2D6 for roughly two days. Any drug broken down by this enzyme — including many antidepressants, antipsychotics, and opioids — will accumulate to higher levels than usual during this window.[18][19]
Contraindications
Concurrent MAOI use is an absolute contraindication — the combination produces life-threatening serotonin syndrome.[35] Tramadol and DXM also carry documented risk of fatal serotonin syndrome.[35]
Relative contraindications include heart conditions, liver impairment (including dose-independent liver toxicity risk[29]), psychotic spectrum conditions, epilepsy,safety citation needed and pregnancy. Clinical trial participants underwent psychiatric medication washout before sessions.[11]
Harm Reduction[edit]
Forms & Identification
MDMA circulates as pressed tablets ("ecstasy"), loose crystals or powder ("molly"), and capsules. Form says nothing reliable about purity — testing consistently shows wide variation across all presentations. Reagent testing provides a useful first screen; quantitative testing services offer substantially more information where available.
Guidelines
- Test every batch with reagent kits at minimum; use quantitative testing services where available
- Start with a measured dose — do not eyeball powder
- Eat a light meal 2–3 hours before dosing to reduce nausea without slowing absorption
- Stay in a cool environment with access to fresh air
- Sip water or electrolyte drinks at a moderate pace — roughly 250–500 mL per hour of physical activity; do not overhydrate
- If redosing, take no more than half the initial dose and wait at least 90 minutes
- Have a sober companion present, especially at higher doses
- Allow at least several weeks between uses to permit serotonin recovery
Set & Setting
MDMA's effects are strongly shaped by environment. Hot, crowded spaces amplify both intensity and physiological risk — particularly overheating. Cool settings with trusted companions produce a qualitatively different and generally safer experience. Unresolved anxiety or interpersonal conflict can intensify during the experience rather than dissolve.
Aftercare & integration. The days after MDMA use often bring low mood, fatigue, irritability, and difficulty concentrating — a direct result of temporary serotonin depletion. Adequate sleep, nutrition, and gentle physical activity support recovery. Social connection and reflection can help process the emotional material that surfaced.
If low mood persists beyond a week, or the experience brought up difficult psychological material, professional support from a therapist familiar with substance experiences is appropriate. Journaling in the first 24–48 hours, while recall is fresh, can preserve insights for later integration.
Recovery & Support
Compulsive MDMA use typically involves escalating doses and shortening intervals — a pattern that produces diminishing effects and worsening comedowns as serotonin stores deplete. Recognizing this cycle is the first step. Gradual spacing of use, supported by honest self-assessment, is more sustainable than abrupt cessation for most people.
Professional support, peer communities, and harm reduction organizations can provide structure for those seeking to change their relationship with MDMA. If MDMA use is entangled with broader substance use or mental health difficulty, integrated treatment addressing all concerns produces better outcomes.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: body temperature hot to the touch through clothing, confusion or loss of consciousness, seizures, chest pain, or inability to stop muscle clenching signal a medical emergency — not normal discomfort. Sudden severe headache or visual disturbance may indicate dangerously low sodium.
Immediate steps:
- Call emergency services if the person is unconscious, seizing, extremely hot, or confused
- Move to a cool area and remove excess clothing
- Apply cool (not ice-cold) water to skin, especially neck and armpits
- If conscious, offer small sips of electrolyte solution — do not force fluids
- Do not leave the person alone
- Place an unconscious but breathing person in the recovery position
What to tell the dispatcher: Name the substance (MDMA/ecstasy), estimated amount, time taken, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from drug-related prosecution.
Legal Status[edit]
MDMA is controlled internationally under Schedule I of the United Nations Convention on Psychotropic Substances (1971). Most countries classify it as prohibited with no recognized medical use, though frameworks for therapeutic access have begun to emerge.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Emergency scheduling July 1985; permanent Schedule I March 1986.[13] FDA Breakthrough Therapy Designation for PTSD granted 2017;[37] NDA rejected August 2024.[6] No approved medical use as of April 2026. |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Possession: up to 7 years imprisonment. Supply: up to life imprisonment. |
| Australia | Schedule 8 (Controlled Drug) | Rescheduled from Schedule 9 effective 1 July 2023.[5] Prescribing permitted by authorized psychiatrists for PTSD under Authorised Prescriber scheme. First country to legally permit medical use. |
| Canada | Schedule III (CDSA) | Health Canada has granted Section 56 exemptions for therapeutic use in some clinical contexts; broad clinical access not yet available. |
| European Union | Nationally scheduled (varies) | Controlled under national law in all member states. International scheduling under UN Convention on Psychotropic Substances, Schedule I. Germany and the Netherlands developing research-use frameworks. |
| International | UN Convention Schedule I | Listed in Schedule I of the United Nations Convention on Psychotropic Substances (1971). |
Legal status changes frequently and varies significantly by jurisdiction. This information reflects the position as of April 2026 and does not constitute legal advice.
references
- [1] ^abPifl C, Nagy G, Berényi S, et al. (2005) Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters — Journal of Pharmacology and Experimental Therapeutics PMID:15831439
- [2]
- [3] ^abFreudenmann RW, Oxler F, Bernschneider-Reif S (2006) The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents — Addiction PMID:16911722
- [4] ^abBenzenhöfer U, Passie T (2010) Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin — Addiction doi:10.1111/j.1360-0443.2010.02948.x
- [5]
- [6] ^abcSingh B (2025) MDMA-Assisted Therapy for Post-Traumatic Stress Disorder: Regulatory Challenges and a Path Forward — CNS Drugs doi:10.1007/s40263-025-01162-y